CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru.
Universidad Científica del Sur, Lima, Peru.
Diabet Med. 2023 Jun;40(6):e15089. doi: 10.1111/dme.15089. Epub 2023 Mar 23.
The use of continuous glucose monitors (CGMs) has been shown to have positive impact on diabetes management for people with type 1 diabetes (T1DM), type 2 diabetes (T2DM) and gestational diabetes (GDM) in high-income countries. However, as useful as CGMs are, the experience in low- and middle-income countries (LMICs) is limited and has not been summarized.
A scoping review of the scientific literature was conducted. Medline, Embase, Global Health and Scopus were used to seek original research conducted in LMICs. The search results were screened by two reviewers independently. We included studies assessing health outcomes following the use of CGMs at the individual level (e.g. glycaemic control or complications) and at the health system level (e.g. barriers, facilitators and cost-effectiveness) in English, Portuguese, Spanish and French. Results were summarized narratively.
From 4772 records found in database search, 27 reports were included; most of them from China (n = 7), Colombia (n = 5) and India (n = 4). Thirteen reports studied T1DM, five T2DM, seven both T1DM and T2DM and two GDM. Seven reports presented results of experimental studies (five randomized trials and two quasi-experimental); two on cost-effective analysis and the remaining 18 were observational. Studies showed that CGMs improved surrogate glycaemic outcomes (HbA reduction), hard endpoints (lower hospitalization rates and diabetes complications) and patient-oriented outcomes (quality of life). However, several caveats were identified: mostly observational studies, few participants in trials, short follow-up and focused on surrogate outcomes.
The scoping review identified that studies about CGMs in LMICs have several limitations. Stronger study designs, appropriate sample sizes and the inclusion of patient-important outcomes should be considered to inform the evidence about CGMs for the management of people with diabetes in LMICs.
在高收入国家,连续血糖监测(CGM)已被证明对 1 型糖尿病(T1DM)、2 型糖尿病(T2DM)和妊娠期糖尿病(GDM)患者的糖尿病管理具有积极影响。然而,尽管 CGM 非常有用,但在中低收入国家(LMICs)的经验有限,且尚未进行总结。
对科学文献进行了范围综述。使用 Medline、Embase、全球健康和 Scopus 检索了在 LMICs 进行的原始研究。两名评审员独立筛选检索结果。我们纳入了评估 CGM 使用后个体层面(如血糖控制或并发症)和卫生系统层面(如障碍、促进因素和成本效益)健康结果的研究,语言为英语、葡萄牙语、西班牙语和法语。结果以叙述方式进行总结。
从数据库搜索中发现的 4772 条记录中,有 27 份报告被纳入;其中大部分来自中国(n=7)、哥伦比亚(n=5)和印度(n=4)。13 份报告研究了 T1DM,5 份研究了 T2DM,7 份研究了 T1DM 和 T2DM,2 份研究了 GDM。7 份报告呈现了实验研究的结果(5 项随机试验和 2 项准实验);2 项关于成本效益分析,其余 18 项为观察性研究。研究表明,CGM 改善了替代血糖结局(HbA 降低)、硬性结局(降低住院率和糖尿病并发症)和以患者为中心的结局(生活质量)。然而,也发现了一些注意事项:主要是观察性研究,试验参与者较少,随访时间短,且侧重于替代结局。
范围综述发现,关于 LMICs 中 CGM 的研究存在一些局限性。应考虑采用更强有力的研究设计、适当的样本量并纳入患者重要结局,以提供有关 CGM 在 LMICs 中管理糖尿病患者的证据。